BACKGROUND: Radiosurgical failure following stereotactic radiosurgery for brain metastases can be attributed to tumor regrowth or radiation necrosis. MRI-guided laser thermal ablation (LTA) therapy has emerged as an option for treatment; however, previous literature demonstrates variable results across centers. OBJECTIVE: To assess the outcomes of LTA in the treatment of metastases failing radiosurgery across multiple centers and to determine if any treatment factors are predictive of outcome. METHODS: Clinical data for 30 patients across 4 centers were retrospectively reviewed. Patients were included if they received LTA therapy following radiosurgical failure due to radiation necrosis or tumor regrowth. Demographics, surgical data, and follow-up imaging and clinical information were collected. Linear regression analyses were performed to determine treatment factors that were associated with post-LTA outcome.
T he use of radiosurgery as a first-line or salvage treatment for brain metastases continues to expand. As a focal, highly precise treatment option, stereotactic radiosurgery (SRS) provides many benefits, including a short treatment timeline, a low probability of normal tissue complication, and a high probability of treated lesion control. 1 However, with increased adoption of this approach also
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FLAIR, fluid-attenuated inversion-recovery; KPS, Karnofsky Performance Scale; LITT, laser interstitial thermal therapy; LOS, length of stay; LTA, laser thermal ablation; OR, odds ratio; SRS, stereotactic radiosurgery comes an increase in incidence of treatment failure. Radiosurgical failure, either due to tumor regrowth or radiation necrosis, can occur in about 10% to 15% of patients still alive at 1 yr. 2 Management of brain metastases after radiosurgical failure depends on patient treatment history but often radiation options have been exhausted early. Traditional craniotomy remains an option for single lesion failures if the lesion is surgically accessible, surgery can be performed with minimal morbidity, and the patient remains with good functional status. For patients who have a single surgically difficult to access lesion or who have one of many lesions that may be symptomatic enough to prevent ongoing systemic cancer treatment, few options exist. Use of chemotherapy for tumor regrowth has limited success and use of immunotherapy for tumor regrowth is often complicated by the need for steroid management of symptoms. Bevacizumab and surgical resection have been shown to be effective in the treatment of radiation necrosis lesions but practically bevacizumab is often difficult to obtain due to restrictions related to FDA approval and insurance reimbursement and often lesions are deep and surgically less accessible. [3] [4] [5] An alternative surgical option for these patients is laser thermal ablation (LTA) for which an increasing body of experience is being developed nationally.
Several recent studies have successfully described the use of MRI-guided LTA for managing brain metastases and support the feasibility of LTA as a surgical treatment option for radiographically regrowing lesions failing radiosurgery. [6] [7] [8] [9] [10] [11] Outcomes however have been variable across centers. We therefore present the first multicentered study looking at LTA in the treatment of metastases failing radiosurgery.
METHODS

Patient Selection
Institutional Review Board approval was obtained to retrospectively review all cases of MRI-guided LTA performed for salvage treatment of brain metastases after radiosurgery at 4 separate institutions: Yale University (10 cases), Cleveland Clinic (7), Washington University St Louis (5), and Wake Forest Medical Center (8) . Patients were consented per each institution's IRB requirement. Patients who had brain metastases previously treated with radiosurgery who then showed radiographic regrowth that was either symptomatic or asymptomatic were included in this study. Radiographic regrowth was defined by the reporting of such a finding by a clinical radiologist at each institution. Lesional growth is typically defined as the increase in any single dimension of a lesion by at least 2 to 3 mm. Suitability of the regrowing lesion for treatment with LTA was determined by the surgeon at each site. An attempt was made in this study to determine the reasons for offering LTA. While patients may have previously undergone SRS to multiple intracranial metastases, all patients in this study only had a single problematic lesion for which LTA treatment was recommended. Of the 30 patients in the study, 14 had only had a single lesion treated with SRS previously, 8 had previously had 2 to 4 brain metastases treated with SRS, and the remaining 8 patients had >5 lesions previously treated with SRS. All cases were performed between September 2010 and November 2013. Patient demographics, clinical cancer data, and all medical, radiation, and surgical treatment data were collected prior and subsequent to LTA. Status of extracranial disease was defined by stable body imaging as reported by each institution. In addition, neurological function data before and after LTA were collected.
Surgical Management
Preoperative Gd contrast-enhanced T1-weighted volumetric images were obtained to allow for visualization, planning, and management. A biopsy was also obtained where possible to determine if lesional growth was due to tumor regrowth or radiation necrosis. Pathology results of the biopsies were retrospectively obtained from the pathology reports at each institution.
All 4 centers utilized the NeuroBlate system (Monteris Medical Inc, Minneapolis, Minnesota) for LTA as described by Sloan et al. 12 The system monitored and reported an expected tissue damage map that informed the surgeon in real time of protein denaturation and cell death zones.
All patients were admitted for observation postoperatively. Steroid treatment was started and continued as needed on an individual patient basis. Patient function was scored using the Karnofsky Performance Scale (KPS) both pre-and post-LTA. Follow-up MRIs were obtained at 1.5, 3, and 6 mo after LTA treatment. Failure of LTA was defined as the regrowth of the ablated lesion on MRI associated with increase in surrounding fluid-attenuated inversion-recovery (FLAIR) and recurrence of symptoms as read by the institution's radiologist.
Imaging Analysis
Imaging was analyzed independently at each site for lesion changes and follow-up response. Given that volumetric measurement of lesion size was not available at any site through standard radiological reporting, volumes of lesions pre-and post-treatment were estimated using the formula: Volume = (length * width * height)/2
Volumes for both gadolinium enhanced lesion size and FLAIR signal abnormality size were measured pretreatment and at each follow-up imaging timepoint. The LTA treatment volume was determined using Monteris M-vision software (Monteris Medical Inc) and reported as a percentage of pretreatment gadolinium volume.
Statistical Analysis
Data are summarized using descriptive statistics. Continuous data were summarized using median, minimum, and maximum. Categorical data were summarized using frequencies and percentages. The association of hospital length of stay (LOS; ≤2 d vs >2 d) and post-LTA surgical and/or medical complications was evaluated using logistic regression. The odds ratio (OR) presented is the odds of LOS >2 d for those with no post-LTA medical/surgical complications vs those with complications. Thus, an OR of 0.09 suggests and decrease in the odds of a >2 d LOS in those with no complications vs those with them. There were no other covariates included in the model. Study outcomes included postsurgical length of survival (based on death or last known follow-up), change in KPS, FLAIR volumes, lesion volumes, and ability to wean off steroids. Multivariable linear regression models were fit for the change in KPS to evaluate the association with select covariates. Repeated measures linear regression models were used to evaluate the association of select covariates with FLAIR and lesion volume. The multivariable linear regression models were adjusted by the baseline values of the outcome. Time to event data was evaluated using right-censored Kaplan-Meier methods. Cox proportion hazards models were used to test for the linear association of select parameters with survival-the only covariates tested were pre-laser interstitial thermal therapy (LITT) volume, pre-LITT FLAIR, and pre-LITT KPS. We looked at the linear relationship with death, so they were treated as continuous in the statistical model.
Statistical analyses were performed with The SAS Software System, version 9.3 (SAS Institute Inc, Cary, North Carolina). In addition, Kaplan-Meier diagrams were produced using R3.2.2 (R Core Team 2015). Statistical significance is being determined at an alpha level of 0.05 (2-sided). Nominal P-values are reported and no adjustments for multiple comparisons are being included for this retrospective review. Data presented as n (% of column total).
RESULTS
Patient Demographic Data and Oncological History
Thirty patients with single lesions treated with LTA were included in the study. These lesions had all initially responded to SRS treatment but subsequently started to regrow radiographically. Patient ages ranged from 29 to 80 yr. The study cohort consisted of 12 men (40%) and 18 women. Median pre-LTA KPS was 80 (range, 50-100).
Primary pathologies were lung cancer in 16/30 (53%) and melanoma in 5/30 (17%). The remaining 9 cases were comprised of breast (3), colon (1), gynecological (2), renal (1), and other (2) cancers. The lesions were located in the frontal lobe (16), parietal lobe (4), occipital lobe (5), temporal lobe (3), insula (1), and basal ganglia (1) .
Of the 30 lesions treated with LTA, 26 lesions were previously treated with single fraction radiosurgery with doses ranging from 15 to 22 Gy prescribed to the edge of the lesion. Three of the lesions received 2 radiosurgical treatments to total doses of 27, 37, and 39 Gy. One lesion received 30 Gy in 4 fractions. Eight patients had undergone previous craniotomy at the site of LTA and 11 patients had undergone prior Whole Brain Radiation Therapy. While all patients had previously undergone chemotherapy treatment, at the time of LTA 19 out of 30 patients (63%) had quiescent extracranial disease and therefore only 11 out of 30 patients (37%) were being treated for progressive disease in the body.
Time from SRS to LTA ranged from 1 to 100 mo (median, 10 mo). A total of 27/30 patients (90%) were symptomatic (7 visual changes, 11 motor, 2 speech, 4 seizures, and 3 with headache) pre-LTA. Median length of symptom duration prior to LTA was 4 mo (range, 0-37 mo). Indications for LTA are shown in Table 1 . The most common indication for use of LTA was steroid resistance or inability to wean steroids.
Clinical Outcomes
Median hospital LOS was 2 d (range, 1-9 d). Shorter LOS was statistically significantly associated with having no post-LTA surgical or medical complications (OR = 0.09, P = .04). Increased hospital LOS was therefore associated with new postoperative deficits and medical comorbidities which included hyperglycemia, hyponatremia, and urinary retention. Median duration of follow-up in this study was 5.9 mo (range, 1-31 mo; Table 2 ). One patient died within 6 wk of the surgery. Two patients had to be salvaged by craniotomy after LTA and 1 patient had repeat LTAs. One additional patient had to be salvaged by both craniotomy and repeat LTA. Local control rate was therefore 92.9% at 6 mo and 83% overall. In the 17% of patients who had recurrence, median time to progression was 6 mo. Twelve out of 27 patients were restarted on systemic therapy for their primary cancer.
Survival
Overall survival rates after LTA were 52.3% at 6 mo, 26.1% at 12 mo, 21.8% at 18 mo, and 16.3% at 30 mo (Table 3) . Cox proportional hazards analysis showed that the only variable with a statistically significant relationship with risk of death was pre-LTA KPS score (P = .038). When subdivided by evidence of ongoing systemic disease (ie, ongoing systemic therapy delivered immediately pre-LTA), there was no statistically significant difference in survival rates (P = .26; Figure 1 ).
Steroid Cessation
Steroid cessation was achieved in 22 out of 30 patients (73.3%) with a median time to cessation of 4.5 wk (range, 1-28 wk; Table 2 ). Of the patients with pre-LTA symptoms and no new post-LTA deficits, 68.4% (13/19) were able to wean off steroids at a median time of 5 wk (2-10 wk). One in 19 died and of the 5/19 who did not cease steroid usage, only 1 saw resolution of their pre-LTA symptoms. Of the patients with new post-LTA deficits, 83.3% (5 out of 6) were able to wean off steroids with a median time of 8 wk (range, 3-28 wk).
Out of 19 patients for whom good steroid use data was available, 11 had symptom relief with steroids pre-LTA and 8 did not. Of the 8 patients whose symptoms did not improve with steroids usage prior to LTA, 5 (63%) had full or partial resolution of their symptoms at a median of 4 wk (range, 2-8 wk). Of the 11 patients whose symptoms did improve with steroid use prior to LTA, 9 (82%) were able to stop steroid usage at a median of 5 wk (range, 1-10 wk) due to full or partial symptom improvement. Percent of patients improving post-LTA was not Survival rates All subjects (n = 30) 52% (12-43), n = 15 26% (12-43), n = 7 22% (9-39), n = 4 1 6 %( 5 -3 4 ) ,n= 1 1 6 %( 5 -3 4 ) ,n= 1 Survival rates excluding patients with KPS < 70 Stable systemic disease (n = 19) 61% (41-91), n = 10 41% (22-75), n = 4 33% (15-69), n = 2 22% (7-65), n = 1 22% (7-65), n = 1 Receiving systemic therapy (n = 11) 56% (31-100), n = 5 22% (7-75), n = 3 11% (2-70), n = 2 11% (2-70), n = 1 11% (2-70), n = 0
Data presented as % of initial (95% CI), n. n represents number of patients alive and not lost to follow-up. statistically different between those improving with steroids pre-LTA and those who did not (P = .23).
FIGURE 1.
Symptom Management
Good postop symptom data were available for 25 patients. Overall, 32% (8/25) of patients had complete resolution of their preop symptoms. Median time to symptom resolution was 2 wk (range, 1-6 wk; Table 2 ). Four out of 25 (16%) had partial resolution and 13/ 25 (52%) had no improvement in their symptoms. Due to intraoperative bleeding, 4 patients had worsening of their preoperative deficits (2 motor and 2 speech). In addition, 1 patient with pre-LTA motor deficit and 1 with pre-LTA vision deficit developed new onset speech difficulty after the procedure.
Changes in KPS from pre-to post-LTA are shown in Table 4 . Fifty-nine per cent (13/22) of patients with a baseline KPS score of 70 or higher had a stable or improved score post-LTA. All patients with baseline KPS scores of 60 or below however deteriorated and died after LTA.
LTA Treatment Results
The pre-LTA lesion volumes ranged from 0.6 to 38.9 cm 3 (median, 7.6 cm 3 ). Pre-LTA FLAIR volumes ranged from 5.2 to 378 cm 3 (median, 55 cm 3 ; Table 5 ). Median operative time was 5.5 h (range, 4-11 h). Biopsies were performed in 24/30 (80%) lesions just prior to LTA. Biopsy results indicated that 5 (21%) of the lesions were due to tumor and 19 (79%) due to radiation necrosis (Table 5 ). Laser power used ranged from 2300 to 125 000 J (median, 28 485 J). A total of 83% to 100% (median, 98%) of the outlined tumor was treated to the protein denaturation line and 41% to 100% (median, 96%) of the lesion was treated to the cell death line (Table 5) . While intraoperative hemorrhage occurred in 4/30 (13%) cases, none occurred due to the biopsy portion of the procedure and none required salvage craniotomy. Change in gadolinium and FLAIR volumes were calculated at 6 wk, 3 mo, and 6 mo post-LTA (Table 6 ). Despite a 34% increase in median gadolinium volume at 6 wk, there was an associated 36% median decrease in FLAIR volume. At 3 mo, median gadolinium volume had returned to pre-LTA baseline but median FLAIR volume had continued to decrease to 74% of original volume. At 6 mo, both median gadolinium and FLAIR volumes were decreased significantly below baseline (34% and 77%, respectively; Figure 2 ).
Simple Linear Regression
Larger reduction in FLAIR volume post-LTA was found to be associated with the increased ability to stop steroids (P = .035). Further, stability of KPS post-LTA was found to be significantly associated with increasing lesion size (P < .001). Table 7 shows median KPS changes by lesion length categories excluding patients with KPS < 70. For patients with pre-LTA KPS scores above 70, LTA treatment with >90% cell death coverage resulted in 4/6 patients (67%) having an increased or stable KPS. This is compared to those with <90% cell death LTA coverage in whom 5 out of 6 (83%) saw a decrease in KPS. This difference was statistically significant (Pearson correlation coefficient Rho = -0.49, P = .015).
No significant associations were found for age, sex, cancer type, histopathology, or pre-LTA treatment with outcome variables. No significant association was found between pre-LTA FLAIR volume, ratio between pre-LTA lesion volume and edema volume, %LTA coverage of lesion with protein denaturation line or cell death line, and %FLAIR reduction or %Gadolinium volume change post-LTA. No statistically significant correlation was found particularly between biopsy pathology and KPS or overall survival outcome. However, 4 of the 5 patients with tumor on their biopsy ultimately had to undergo a salvage surgical procedure using repeat LTA or craniotomy.
DISCUSSION
LTA is a procedure that destroys tissue through the generation of heat causing focal hyperthermic injury to cells at the membrane and subcellular levels. 7, 13 The modality provides sharp boundaries of the thermal ablation zone and is faster than other thermal techniques such as cryoablation, high-intensity focused ultrasound, and radiofrequency ablation. 7 Compared to other thermoablation techniques, a fundamental advantage of using laser energy is that it can be coupled through MRI compatible optical fibers.
14 Several studies have now successfully described the use of magnetic resonance-guided thermal therapy for managing intracranial neoplasms. For patients with brain metastases, LTA has been shown to be an effective option for patients with medically refractory radiation necrosis or with resistant brain metastases not amenable to surgical decompression. 7, 8 In addition to lesional control, several studies have also reported the use of LTA in the control of perilesional edema which in itself can result in significant symptom relief and cessation of steroids. 8, 10, 15 Many other single institutional series are now being published demonstrating similar feasibility and with equally promising but highly variable results. 9, 11 There is therefore a need to more clearly identify the patient population that can benefit the most from this novel treatment or at least the patients for whom this treatment may not offer benefit. In addition, there is a need to determine if variances in clinical approach across institutions have an effect on outcomes. This study is the first collection of multicentered data looking at LTA in the treatment of lesions regrowing after radiosurgery.
This study showed that across all 4 centers, the most common indications for use of LTA in a lesion regrowing after radiosurgery were steroid resistance or dependence and presence of a lesion that looked surgically amenable to LTA. The results of this study showed that 73% of LTA-treated patients were able to wean off Gadolinium 34% (-83 to 188), n = 28 a 2% (-96 to 196), n = 17 a -34% (-97 to 267), n = 14 a FLAIR -36% (-95 to 110), n = 24 a -74% (-100 to 1125), n = 14 a -77% (-100 to 899), n = 13 a a n represents number of patients with data which is reduced from 30 due to missing data or death. Data presented as percent change (95% CI), n. steroids at a median time of 4.5 wk. Patients most likely to be able to wean off steroids were those with larger reduction in FLAIR volume after LTA. Given the retrospective nature of this study, however, the ability to wean patients off steroids was at the discretion of each surgeon and therefore results using this end point may represent surgeon bias. The imaging changes following LTA are well demonstrated in this study. Regardless of pathology, this study suggests a KPS outcome advantage if >90% cell death coverage of the lesion is achieved. To ensure cell death thermal coverage to the edge of the lesion, the post-LTA gadolinium image would then be expected to show enhancement larger than the pre-LTA lesion. While this enlargement may seem concerning, it is robustly associated with a progressive decrease in the amount of associated surrounding FLAIR signal suggesting a decrease in edema. Given the lack of a standardized method by which FLAIR volume is calculated, FLAIR volume in this study was estimated using the same volumetric formula as for intracerebral hematomas. Given that FLAIR volume was estimated on each scan using this technique, we have used this estimated volume for comparison. Following LTA, we found an estimated 36% decrease in the amount of surrounding FLAIR abnormality seen as early as 6 wk post-LTA and ultimately a 75% decrease in the FLAIR volume by 3 to 6 mo. Lack of this decrease therefore could represent either incomplete treatment of the lesion or FLAIR signal abnormality unrelated to the lesion (such as leuko-encephalopathic changes following prior brain irradiation). A more detailed radiographic analysis of future NEUROSURGERY VOLUME 82 | NUMBER 1 | JANUARY 2018 | 61 series may be needed to determine the reason for these imaging discrepancies and how they affect outcome post-LTA.
Local lesional control rate after LTA in this cohort was 92.9% at 6 mo and 83% overall resulting in 44% of patients experiencing partial or complete resolution of symptoms post-LTA. Median time to symptom resolution was 2 wk. Similar to previous reports, LTA procedures were performed with few intraoperative complications and median LOS in the hospital was 2 d. Four out of 30 cases showed evidence of intraoperative hemorrhage on postop imaging. None of the hemorrhages occurred at the time of biopsy (as evidenced by postbiopsy intraoperative imaging) and none were of large enough volume to require salvage craniotomy. Intraoperative hemorrhage therefore likely occurred at the time of LTA itself and may be related to either hemorrhagic tendency of the lesion during coagulation or speed of energy delivery. Future studies are needed to clarify the causative factors to limit the risk for hemorrhage in these procedures. While rates of postoperative neurological and medical complications were 23% in this cohort and 20% of patients developed new neurological deficits, these results are also not too dissimilar to previously reported rates. The largest case series to date looking at radiological local control with LTA (for the treatment of recurrent lesions after stereotactic radiosurgery for brain metastases) reported 75.8% local control at a median follow-up of 6 mo. 11 In addition, the 92.9% rate in this study is likely equivalent to the 90.7% control rate reported by Kwon et al 16 using repeat radiosurgery for recurrent metastatic tumors.
Survival after LTA was singularly dependent on KPS. Despite 63% of our patients having quiescent systemic disease at the time of LTA, this study showed overall survival rates of 62% at 6 mo and 30% to 36% at 12 to 18 mo, rates similar to those reported in the literature. 10, 11 With separation of the groups into whether or not they were receiving systemic therapy for ongoing active cancer in the body, we note that while 6-mo survival rates are very similar, long-term (>12 mo) survival rates are doubled in the patients in whom systemic disease is well controlled compared with those who were receiving cancer treatment at the time of LTA. These data suggest that LTA will likely result in better outcome in patients whose systemic disease is quiescent but is not necessarily contraindicated in those who are still getting cancer treatment. In this cohort, biopsy pathology was not correlated with local lesional control but only 5 out of 24 (21%) of lesions were positive for tumor. It is important to note that 4 of the 5 patients with tumor on their biopsy ultimately underwent a salvage surgical procedure vs none of the patients whose biopsies demonstrated radiation necrosis. No information was available for the fifth patient with tumor. The inability to demonstrate a difference between outcomes may be then related to the small numbers in this study. If the apparent difference is real, then it may be important to obtain a biopsy for all LTA patients and possibly consider changing treatment paradigms for these patients in real time. We are currently conducting a prospective study of radiation necrosis and metastatic tumor patients who underwent LITT for salvage treatment of brain metastases after radiosurgery in order to elucidate potential differences in these groups. Given that it is well known that any tumor that is not ablated will continue to grow, it may be worth considering increasing the percentage of lesion ablated to ensure tumor control where possible and perhaps the patient should be restarted on systemic therapy early after LTA. Furthermore, in interpreting these results, it is important to recognize that biopsy results can be falsely negative for tumor due to sampling error. Given that the finding of tumor may ultimately influence intraoperative LTA management or postoperative treatment algorithms, multifocal biopsies or biopsies based on more sophisticated preoperative imaging such as brain positron emission tomographic or MR perfusion may be warranted to try to improve diagnostic accuracy.
With regard to KPS and outcome, patients with lesions >3 cm and those with a KPS >70 had the most statistically favorable outcomes while patients with a KPS score <60 were unlikely to be salvageable. In addition, while statistically not significant, there was a suggestion within the cohort that in those with KPS >70, cell death coverage of >90% during LTA treatment might result in stability or improvement in post-LTA KPS. This finding is similar to those of Sloan et al 17 noted when treating primary intracranial neoplasms. In this cohort, patients with higher KPS tended to have smaller lesions, and patients without symptoms pre-LTA had on average, more favorable changes in KPS after the procedure.
Limitations
This is a small albeit multicentered retrospective study. The findings in this study could therefore be limited or biased by its small size and the lack of standardization of patient selection and treatment technique. There were no prespecified hypothesis tests, and the study was not powered to make statistical comparisons. Caution should be made when evaluating P-values as there was no adjustment made for multiple comparisons, and the sample size is small.
This along with many of the findings in this study therefore needs to be validated by a larger and/or prospective collected study.
CONCLUSION
In patients with metastatic brain lesions failing radiosurgery, MR-guided LTA therapy provides a feasible surgical treatment alternative. In the majority of patients, LTA treatment has a low intraoperative complication rate, only requires a 1 to 2 d hospital stay and is most successful at achieving a rapid and sustained reduction in the amount of perilesional edema that translates into cessation of steroids in about 75% of these patients and symptom improvement in about 50%-as compared to likely progressive decline in the majority of these patients with steroid-only therapy. While the success of LTA is still difficult to predict, this study suggests that LTA may be more effective or less morbid in patients with larger lesions and a higher pre-LTA KPS. To improve success, it may be necessary to get patients in for surgery earlier before KPS declines. In addition, patients with stable systemic disease (as defined by being off systemic therapy at the time of LTA), good cell death coverage at time of treatment and no postoperative complications may likely have better results post-LTA. A larger or more standardized cohort is needed to confirm the findings in this study. Furthermore, for patients with radiation necrosis, once it is determined which patients might benefit most from LTA, this group then needs to be compared to equivalent patients receiving Avastin (bevacizumab; Genentech, San Francisco, California) in order to further assist in management decision making.
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